PLEASANTON, Calif., Aug. 17, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that visionaries from Amgen, Bristol Myers Squibb, Daiichi Sankyo, Merck, and Takeda will be keynote speakers at the upcoming 2023 Veeva R&D and Quality Summit in Boston on Sept. 13 and 14. Biopharma leaders will share how new strategies and technology across clinical, regulatory, safety, and quality are moving the industry forward with speed and efficiency.
As one of the largest life sciences events, Veeva R&D and Quality Summit will bring together more than 2,000 executives to share learnings across more than 90 sessions. Veeva CEO Peter Gassner will kick off the opening keynote with advancements that can help sponsors, contract research organizations (CROs), and research sites streamline product development to benefit patients. Additional featured keynotes and sessions include:
"Veeva R&D and Quality Summit brings together life sciences leaders from across the globe to learn, share insights, and innovate," said Jim Reilly, vice president of Veeva Development Cloud strategy. "This event serves as an epicenter for networking with peers, discussing industry trends, and discovering new technologies that can accelerate the development of treatments and medicines."
The event is open exclusively to life sciences professionals. Register and stay up to date on the agenda at veeva.com/Summit.
Additional Information
Register for Veeva R&D and Quality Summit: veeva.com/Summit/register Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Contact: | |
Deivis Mercado |
Last Trade: | US$217.02 |
Daily Change: | 7.02 3.34 |
Daily Volume: | 773,766 |
Market Cap: | US$35.140B |
September 05, 2024 September 05, 2024 August 28, 2024 August 22, 2024 August 13, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB